Detail akcie Veru Rg online

Business Summary: Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Veru Inc revenues was not reported. Net loss before extraordinary items decreased 56% to $15.7M. Lower net loss reflects Biopharmaceutical segment loss decrease of 32% to $24.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.61 to -$1.07.